[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 564,107,264
  • Shares Outstanding, K 2,407,217
  • Annual Sales, $ 94,193 M
  • Annual Income, $ 26,804 M
  • EBIT $ 23,115 M
  • EBITDA $ 30,618 M
  • 60-Month Beta 0.27
  • Price/Sales 5.92
  • Price/Cash Flow 16.41
  • Price/Book 6.87

Options Overview Details

View History
  • Implied Volatility 21.44% (-0.27%)
  • Historical Volatility 18.36%
  • IV Percentile 67%
  • IV Rank 51.61%
  • IV High 29.89% on 03/27/26
  • IV Low 12.42% on 07/24/25
  • Expected Move (DTE 5) 4.10 (1.75%)
  • Put/Call Vol Ratio 0.10
  • Today's Volume 91,911
  • Volume Avg (30-Day) 22,931
  • Put/Call OI Ratio 0.83
  • Today's Open Interest 353,385
  • Open Int (30-Day) 346,192
  • Expected Range 230.24 to 238.44

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $2.83
  • Number of Estimates 8
  • High Estimate $2.88
  • Low Estimate $2.69
  • Prior Year $2.77
  • Growth Rate Est. (year over year) +2.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
220.37 +6.34%
on 05/11/26
235.49 -0.49%
on 05/22/26
+8.24 (+3.64%)
since 04/22/26
3-Month
220.37 +6.34%
on 05/11/26
251.71 -6.90%
on 03/02/26
-8.15 (-3.36%)
since 02/20/26
52-Week
149.04 +57.23%
on 06/20/25
251.71 -6.90%
on 03/02/26
+81.73 (+53.55%)
since 05/22/25

Most Recent Stories

More News
3 Vanguard Dividend Funds for Low-Cost Income

Dividend funds help you diversify while collecting equity income. You can keep more of that income thanks to the low fees on these Vanguard dividend funds.

AAPL : 308.82 (+1.26%)
AVGO : 414.14 (-0.10%)
VHYAX : 47.84 (+0.91%)
JPM : 306.38 (+1.12%)
JNJ : 234.34 (+1.13%)
VYM : 158.70 (+0.92%)
NSRGY : 100.5500 (-0.16%)
HSBC : 92.02 (-0.03%)
VIHAX : 48.30 (-0.25%)
VIG : 233.10 (+0.89%)
XOM : 154.92 (-0.24%)
VYMI : 99.76 (-0.39%)
3G Capital Exits Microsoft Stock in Major Portfolio Shift. MSFT Is Still One of the Best AI Plays Now.

3G Capital dumped Microsoft stock and piled into semiconductor names. Here's what the move says about AI investing right now, and whether MSFT remains a buy.

MSFT : 418.57 (-0.12%)
BABA : 130.00 (-1.12%)
BAYRY : 11.1100 (-1.51%)
JNJ : 234.34 (+1.13%)
MBGAF : 58.0750 (-0.02%)
ACN : 179.24 (+0.77%)
RHHBY : 53.3400 (+1.20%)
3 Gold-Rated Index Funds We Love Right Now

These index funds are driven by well-crafted benchmarks and charge vanishingly thin fees.

VHYAX : 47.84 (+0.91%)
CSCO : 120.41 (+1.87%)
FSMDX : 40.76 (+0.82%)
JPM : 306.38 (+1.12%)
FUMBX : 10.24 (-0.10%)
JNJ : 234.34 (+1.13%)
XOM : 154.92 (-0.24%)
VYM : 158.70 (+0.92%)
Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation

WASHINGTON , May 14, 2026 /PRNewswire/ -- A new global survey of patient and urologist perception and experience—conducted in collaboration with leading bladder cancer professional and patient...

JNJ : 234.34 (+1.13%)
STGW : 6.51 (+3.50%)
Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwaveâ„¢ C2 Aero Coronary IVL Catheter

Next-generation intravascular lithotripsy (IVL) catheter resets physicians’ expectations by addressing unmet needs in deliverability, lesion crossing and balloon repositioning ...

JNJ : 234.34 (+1.13%)
Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 47 th Annual Global Healthcare Conference on Tuesday, June 9 th , 2026. Management will participate in a...

JNJ : 234.34 (+1.13%)
Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP

Oral presentations feature CAPLYTA ® long-term data assessing relapse risk reduction in schizophrenia and new seltorexant analyses in major depressive disorder (MDD) with insomnia symptoms...

JNJ : 234.34 (+1.13%)
3 Dividend Aristocrats With Soaring Profits That Wall Street Says to Buy Now

3 Dividend Aristocrats with strong profit growth, safe payout ratios, decades of raises, and Buy-rated Wall Street support.

IBM : 253.84 (+0.34%)
PPG : 107.78 (+1.08%)
JNJ : 234.34 (+1.13%)
Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission

Generation Fine launches after global survey finds nearly 4 in 5 patients living with major depressive disorder don't believe antidepressants will help them reach remission

JNJ : 234.34 (+1.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among...

See More

Key Turning Points

3rd Resistance Point 238.42
2nd Resistance Point 236.96
1st Resistance Point 235.65
Last Price 234.34
1st Support Level 232.88
2nd Support Level 231.41
3rd Support Level 230.10

See More

52-Week High 251.71
Last Price 234.34
Fibonacci 61.8% 212.49
Fibonacci 50% 200.38
Fibonacci 38.2% 188.26
52-Week Low 149.04

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.